Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”As I close the chapter on ASH2025, I’m energized by the conversations happening across the hematology community.
Being on the ground at conferences like ASH is so important for our work in rare blood disorders.
It’s where we connect with the researchers advancing the science, the clinicians treating patients every day, and the advocates representing the communities we serve – a convergence of those who have a real stake in the research, the data, and the outcomes.
The breadth of scientific innovation presented this year was impressive.
I heard a lot about the potential of multi-immune modulation as an approach to rare autoimmune conditions like Immune Thrombocytopenia (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and Sickle Cell Disease (SCD).
While hemophilia remains core to our mission, I’ve enjoyed expanding our scientific discussions with healthcare providers who manage patients with Complex Immune Dysregulation (CID) conditions.
There’s clearly significant room for improvement for these patients who often have no treatments approved specifically for their condition.
These face-to-face conversations remind us why we do what we do.
A red thread throughout all my discussions was how our work translates to real impact in patients’ daily lives.
Hearing directly from the hematology community about the challenges they face, the progress being made, and the work still ahead helps inform our path forward.
What were some of your key learnings from the meeting?”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 17:55Can We Prevent Postpartum Blood Clots without Putting Most Women on Heparin? – RPTH Journal
-
Jun 9, 2026, 17:54Lucky Oseghale Oloboh: Health Is Power, Health Is Personal, and Health Is Our First Responsibility in Life’s Journey on Mother Earth
-
Jun 9, 2026, 17:53Ajay Samkaria: How ABO Subgroups Directly Impact Transfusion Safety
-
Jun 9, 2026, 17:51Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity
-
Jun 9, 2026, 17:50Mary Cushman: It’s Time to Apply to Be on an ISTH SSC
-
Jun 9, 2026, 15:56Wolfgang Miesbach: A New Genetic Perspective on the Worldwide Burden of von Willebrand Disease
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD